Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

导出 LinkOut

翻译打印收藏纠错

作者： Lorant,Gonczi ^[1] ; Zsuzsanna,Vegh ^[1] ; Petra Anna,Golovics ^[1] ; Mariann,Rutka ^[2] ; Krisztina Barbara,Gecse ^[1] ; Renata,Bor ^[2] ; Klaudia,Farkas ^[2] ; Tamás,Szamosi ^[3] ; László,Bene ^[4] ; Beáta,Gasztonyi ^[5] ; Tünde,Kristóf ^[6] ; László,Lakatos ^[7] ; Pál,Miheller ^[8] ; Károly,Palatka ^[9] ; Mária,Papp ^[9] ; Árpád,Patai ^[10] ; Ágnes,Salamon ^[11] ; Gábor Tamás,Tóth ^[12] ; Áron,Vincze ^[13] ; Edina,Biro ^[14] ; Barbara Dorottya,Lovasz ^[1] ; Zsuzsanna,Kurti ^[1] ; Zoltan,Szepes ^[2] ; Tamás,Molnár ^[2] ; Péter L,Lakatos ^[1]

作者单位： First Department of Internal Medicine, Semmelweis University, Budapest, Hungary. ^[1] First Department of Medicine, University of Szeged, Szeged, Hungary. ^[2] Military Hospital - State Health Centre, Budapest, Hungary. ^[3] First Department of Medicine, Peterfy Hospital, Budapest, Hungary. ^[4] Second Department of Medicine, Zala County Hospital, Zalaegerszeg, Hungary. ^[5] Second Department of Medicine, B-A-Z County and University Teaching Hospital, Miskolc, Hungary. ^[6] Department of Internal Medicine, Csolnoky Ferenc Regional Hospital, Veszprém, Hungary. ^[7] Second Department of Internal Medicine, Semmelweis University, Budapest, Hungary. ^[8] Institute of Medicine, Department of Gastroenterology, University of Debrecen, Clinical Center, Debrecen, Hungary. ^[9] Department of Medicine and Gastroenterology, Markusovszky Hospital, Szombathely, Hungary. ^[10] Department of Gastroenterology, Tolna County Teaching Hospital, Szekszárd, Hungary. ^[11] Department of Gastroenterology, Janos Hospital, Budapest, Hungary. ^[12] First Department of Medicine, University of Pécs, Pécs, Hungary. ^[13] Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary. ^[14]

关键词 Biosimilar infliximab inflammatory bowel diseases